Four transmembrane tyrosine kinase receptors from the EGF receptor (EGFR) or HER proto-oncogene family, which are involved in the etiology of many malignancies, such as ovarian cancer, are known to be significant therapeutic targets. The gene discussed is EGFR; the disease is ovarian carcinoma.